RecruitingPhase 2NCT05237388

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

Sponsor

Duke University

Enrollment

75 participants

Start Date

Apr 20, 2023

Study Type

INTERVENTIONAL

Conditions

Chronic Kidney Diseases

Summary

The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD).

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This trial tests whether a JAK inhibitor — a type of anti-inflammatory drug — can slow down kidney disease caused by a specific high-risk gene variant called APOL1, which is more common in people of African descent. **You may be eligible if...** - You are 18 to 70 years old - You carry the high-risk APOL1 gene variant (G1/G1, G2/G2, or G1/G2) - You have been diagnosed with a kidney disease called FSGS (a type of kidney scarring) or high-blood-pressure-related chronic kidney disease - Your protein leak in urine (UACR) is 300 mg/g or above - Your kidney function (eGFR) is 26 or above **You may NOT be eligible if...** - You have diabetes, HIV, or sickle cell disease - You have had a kidney transplant - You are pregnant or nursing - You are currently taking a JAK inhibitor or strong immune-suppressing medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.